Peter Ostler

Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations based on Eastern Cooperative Oncology Group performance status (ECOG PS) in TRITON3.

M. Neil Reaume, Karim Fizazi, Alan H. Bryce, Simon Chowdhury et autres

ca, fr, us, gb, es, it, au, il, dk (code pays fourni par la source)

Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)

Raguprakash Ratnakumaran, Victoria Hinder, Andrew K. Chan, Shaun Tolan et autres

gb, ie, nz (code pays fourni par la source)

Clinical Evaluation of Stereotactic Ablative Radiotherapy for Oligometastases From Rare Primary Cancers

Rupinder Talwar, P. Nariyangadu, Peter Hoskin, Adéle Stewart-Lord et autres

gb, ca (code pays fourni par la source)

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial

Alison Tree, Victoria Hinder, Shaun Tolan, Peter Ostler et autres

gb, ca, ie, nz (code pays fourni par la source)

3743 Predictors of outcome for focal HDR salvage prostate brachytherapy in locally relapsed prostate cancer

Amani A. Chowdhury, Roberto Alonzi, Peter Ostler, Milan Anjanappa et autres

3807 Long-term outcomes of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer: A multicentered retrospective analysis

Wiwatchai Sittiwong, Anna Lydon, James Wylie, John Logue et autres

MP16-07 RUCAPARIB VS DOCETAXEL OR SECOND-GENERATION ANDROGEN RECEPTOR PATHWAY INHIBITOR THERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH BRCA MUTATIONS WITH OR WITHOUT LIVER METASTASES IN TRITON3

David Morris, Alan H. Bryce, Josep M. Piulats, M. Neil Reaume et autres

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer

Gianmarco Leone, Francesco Orlando, Peter Dutey‐Magni, Osvaldas Vainauskas et autres

gb, it (code pays fourni par la source)

Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.

Alan H. Bryce, Josep M. Piulats, M. Neil Reaume, Peter Ostler et autres

us, ie, es, ca, gb, dk, it, fr (code pays fourni par la source)

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

Nicholas van As, Clare Griffin, Alison Tree, Jaymini Patel et autres

gb (code pays fourni par la source)

Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial

Nicholas van As, Binnaz Yasar, Clare Griffin, Jaymini Patel et autres

gb (code pays fourni par la source)

Single–dose high-dose-rate brachytherapy versus two and three fractions for locally advanced prostate cancer

Peter Hoskin, Ana M. Rojas, Peter Ostler, Robert Hughes et autres

gb (code pays fourni par la source)